| Sector | Prev | Curr ▼ | Delta |
|---|---|---|---|
| Pharmaceuticals & Biotechnology | 64.9% | 67.8% | ▲ +2.9% |
| Healthcare Services | 20.4% | 17.9% | ▼ -2.5% |
| Insurance | 6.3% | 7.3% | ▲ +1.0% |
| Retailing | 1.6% | 1.6% | ● +0.0% |
| IT - Services | 1.3% | 1.6% | ▲ +0.3% |
| Healthcare Equipment & Supplies | 1.4% | 1.1% | ▼ -0.3% |
| Sector | Prev | Curr ▼ | Delta |
|---|---|---|---|
| Pharmaceuticals & Biotechnology | 67.8% | 68.5% | ▲ +0.7% |
| Healthcare Services | 17.9% | 17.5% | ▼ -0.4% |
| Insurance | 7.3% | 7.3% | ● 0.0% |
| Retailing | 1.6% | 1.7% | ● +0.0% |
| IT - Services | 1.6% | 1.5% | ● 0.0% |
| Healthcare Equipment & Supplies | 1.1% | 1.0% | ▼ -0.1% |
Comparing Apr 2026 → May 2026
| # | Stock | Sector | Weight (May 2026) |
|---|---|---|---|
| 1 | Zydus Lifesciences Limited ₹10.78 Cr |
Pharmaceuticals & Biotechnology | 1.98% |
| # | Stock | Sector | Last Weight (Apr 2026) |
|---|---|---|---|
| 1 | Jupiter Life Line Hospitals Ltd ₹5.52 Cr |
Healthcare Services | 1.04% |
| 2 | Cohance Lifesciences Limited ₹5.10 Cr |
Pharmaceuticals & Biotechnology | 0.96% |
| 3 | Rainbow Childrens Medicare Limited ₹7.40 L |
Healthcare Services | 0.01% |
| # | Stock | Sector | Apr 2026 | May 2026 | Change |
|---|---|---|---|---|---|
| 1 | Divi's Laboratories Limited ₹20.00 Cr |
Pharmaceuticals & Biotechnology | 2.07% | 3.68% | +1.61% |
| 2 | Laurus Labs Limited ₹31.33 Cr |
Pharmaceuticals & Biotechnology | 4.78% | 5.76% | +0.98% |
| 3 | Apollo Hospitals Enterprise Limited ₹25.35 Cr |
Healthcare Services | 4.32% | 4.66% | +0.34% |
| 4 | Acutaas Chemicals Ltd ₹11.29 Cr |
Pharmaceuticals & Biotechnology | 1.76% | 2.07% | +0.31% |
| 5 | Aster DM Healthcare Limited ₹17.12 Cr |
Healthcare Services | 2.97% | 3.15% | +0.18% |
| 6 | Max Financial Services Limited ₹6.65 Cr |
Insurance | 1.05% | 1.22% | +0.17% |
| 7 | Concord Biotech Limited ₹7.88 Cr |
Pharmaceuticals & Biotechnology | 1.29% | 1.45% | +0.16% |
| 8 | Metropolis Healthcare Limited ₹6.94 Cr |
Healthcare Services | 1.12% | 1.28% | +0.16% |
| 9 | Abbott India Limited ₹29.54 Cr |
Pharmaceuticals & Biotechnology | 5.28% | 5.43% | +0.15% |
| 10 | Nephrocare Health Services Ltd ₹8.98 Cr |
Healthcare Services | 1.50% | 1.65% | +0.15% |
| # | Stock | Sector | Apr 2026 | May 2026 | Change |
|---|---|---|---|---|---|
| 1 | Gland Pharma Limited ₹2.25 Cr |
Pharmaceuticals & Biotechnology | 2.09% | 0.41% | -1.68% |
| 2 | Mankind Pharma Limited ₹17.82 L |
Pharmaceuticals & Biotechnology | 1.27% | 0.03% | -1.24% |
| 3 | Sun Pharmaceutical Industries Limited ₹49.48 Cr |
Pharmaceuticals & Biotechnology | 9.38% | 9.09% | -0.29% |
| 4 | Lupin Limited ₹31.75 Cr |
Pharmaceuticals & Biotechnology | 6.09% | 5.83% | -0.26% |
| 5 | Ajanta Pharma Limited ₹8.79 Cr |
Pharmaceuticals & Biotechnology | 1.86% | 1.61% | -0.25% |
| 6 | IPCA Laboratories Limited ₹28.20 Cr |
Pharmaceuticals & Biotechnology | 5.34% | 5.18% | -0.16% |
| 7 | Poly Medicure Limited ₹5.14 Cr |
Healthcare Equipment & Supplies | 1.09% | 0.95% | -0.14% |
| 8 | ICICI Prudential Life Insurance Company Limited ₹14.61 Cr |
Insurance | 2.81% | 2.69% | -0.12% |
| 9 | Glenmark Pharmaceuticals Limited ₹14.22 Cr |
Pharmaceuticals & Biotechnology | 2.72% | 2.61% | -0.11% |
| 10 | Fortis Healthcare Limited ₹23.21 Cr |
Healthcare Services | 4.35% | 4.27% | -0.08% |
33 stocks — May 2026
| # | Stock | Sector | Cap | Weight & Value |
|---|---|---|---|---|
| 1 |
₹49.48 Cr |
Pharmaceuticals & Biotechnology |
9.09%
|
|
| 2 |
₹31.75 Cr |
Pharmaceuticals & Biotechnology |
5.83%
|
|
| 3 |
₹31.33 Cr |
Pharmaceuticals & Biotechnology |
5.76%
|
|
| 4 |
₹29.54 Cr |
Pharmaceuticals & Biotechnology |
5.43%
|
|
| 5 |
₹28.67 Cr |
Pharmaceuticals & Biotechnology |
5.27%
|
|
| 6 |
₹28.20 Cr |
Pharmaceuticals & Biotechnology |
5.18%
|
|
| 7 |
₹25.35 Cr |
Healthcare Services |
4.66%
|
|
| 8 |
₹23.84 Cr |
Pharmaceuticals & Biotechnology |
4.38%
|
|
| 9 |
₹23.21 Cr |
Healthcare Services |
4.27%
|
|
| 10 |
₹22.44 Cr |
Pharmaceuticals & Biotechnology |
4.12%
|
Disclaimer: Data sourced from individual AMC monthly portfolio disclosures, as mandated by SEBI/AMFI. While we strive for accuracy, errors in parsing or presentation may occasionally occur. This is not investment advice. Please consult a SEBI-registered investment adviser before making any investment decisions.
Found a discrepancy or have feedback? Contact Us — we read every message personally.